Treatment Challenges Associated with Breast Cancer and Chemotherapeutic Drug Resistance
DOI:
https://doi.org/10.47672/ajhmn.1695Keywords:
Chemotherapy, Drug Resistance, Risk Factors, Breast CancerAbstract
Purpose: The most frequent form of cancer in women worldwide and the main factor in mortality from cancer, breast cancer is a common malignancy.
Materials and Methods: In 2012, there were 521,900 cancer deaths and an estimated 1.7 million new cases of cancer (or 25% of all cancer kinds).
Findings: Women are at risk for breast cancer for a variety of reasons, but breast density, genetic predisposition, age, and estrogen dysregulation stand out. A heterogeneous illness like breast cancer is brought on by shared ecological and hereditary factors. Development of novel molecularly targeted therapeutics is facilitated by a thorough understanding of the genesis of breast cancer. Numerous variables, including tumor size, lymph node involvement, and the presence of estrogen, progesterone, and HER2 receptors, determine the therapeutic efficacy of chemotherapy. One of the main issues with cancer chemotherapy, particularly in the case of breast tumors, is drug resistance. In order to achieve this, a number of active trials are investigating brand-new medication combinations that aim to block important signaling pathways that contribute to the development of disease.
Implications to Theory, Practice and Policy: These therapeutic advancements may help individuals with breast cancer overcome their treatment resistance. Additionally, finding additional biomarkers and possible drug targets may help to create new chemotherapeutic combinations that eventually increase the effectiveness of these combination therapies.
Downloads
References
Ferlay J (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 136: E359-E386.
Luo M (2009) Genome comparisons reveal a dominant mechanism of chromosome number reduction in grasses and accelerated genome evolution in Triticeae. Proceedings of the National Academy of Sciences. 106: 15780-15785.
Siegel R.L, K D Miller and A Jemal (2015) Cancer statistics, 2015. CA: a cancer journal for clinicians. 65: 5-29.
McGuire, S (2016) World cancer report 2014. Geneva, Switzerland: World Health Organization, international agency for research on cancer, WHO Press, 2015. Oxford University Press.
Ferlay J (2018) GLOBOCAN 2012 v1. 0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2014. Available from: globocan. iarc. fr,.
Ostry V (2017) Mycotoxins as human carcinogens-the IARC Monographs classification. Mycotoxin research. 33: 65-73.
Torre L A (2015) Global cancer statistics, 2012. CA: a cancer journal for clinicians. 65: 87-108.
Siegel R L, K D Miller and A Jemal (2016) Cancer statistics, 2016. CA: a cancer journal for clinicians. 66: 7-30.
Wang, K (2016) Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology and End Results database. Cancer. 122: 30693074.
Siegel R K Miller and A Jemal (2016) Cancer statistics, 2016 CA Cancer J Clin 66: 7-30.
Singletary S E (2003) Rating the risk factors for breast cancer. Annals of surgery. 237: 474.
Colditz, G A (1993) Family history, age, and risk of breast cancer: prospective data from the Nurses' Health Study. Jama, 270: 338-343.
Friedenreich C (2001) Review of anthropometric factors and breast cancer risk. European journal of cancer prevention, 10: 15-32.
Clemons M. and P Goss (2001) Estrogen and the risk of breast cancer. New England Journal of Medicine. 344: 276-285.
Schousboe J T (2011) Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Annals of internal medicine. 155: 10-20.
Tice J A and K Kerlikowske (2009) Screening and prevention of breast cancer in primary care. Primary Care: Clinics in Office Practice. 36: 533-558.
Lynch H T (1990) Clinical/genetic features in hereditary breast cancer. Breast cancer research and treatment. 15: 63-71.
Pace L E and N L Keating (2014) A systematic assessment of benefits and risks to guide breast cancer screening decisions. Jama. 311: 1327-1335.
Sørlie T (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences. 98: 1086910874.
Perou C M (2000) Molecular portraits of human breast tumours. nature,. 406: 747-752.
Polyak K (2011) Heterogeneity in breast cancer. The Journal of clinical investigation. 121: 3786-3788.
Polyak K (2007) Breast cancer: origins and evolution. The Journal of clinical investigation. 117: 3155-3163.
Chaffer C L (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences. 108: 7950-7955.
Proia T A (2011) Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate Cell stem cell. 8: 149-163.
Lim E (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature medicine. 15: 907.
Higgins M J and J Baselga (2011) Targeted therapies for breast cancer. The Journal of clinical investigation. 121: 3797-3803.
Slamon D J (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England journal of medicine. 344: 783-792.
Vogel C L (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20: 719-726.
Cobleigh M A (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of clinical Oncology. 17: 2639-2639.
Romond E H (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England journal of medicine. 353: 1673-1684.
Alvarez R H, V Valero and G N Hortobagyi (2010) Emerging targeted therapies for breast cancer. J Clin Oncol. 28: 33663379.
Miller K (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine. 357: 2666-2676.
Group E B C T C (1998) Tamoxifen for early breast cancer: an overview of the randomised trials The Lancet. 351: 14511467.
Makhoul I (2018) Therapeutic strategies for breast cancer, in The Breast Elsevier. 315-330.
Howlader N (2015) SEER cancer statistics review, 1975- 2012. Bethesda, MD: National Cancer Institute.
Carey L A (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical cancer research. 13: 2329-2334.
Sparano J A (2015) Prospective validation of a 21-gene expression assay in breast cancer. New England Journal of Medicine. 373: 2005-2014.
Smith R A (2017) Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA: a cancer journal for clinicians. 67: 100-121.
Abrams J S (2001) Adjuvant therapy for breast cancer-results from the USA consensus conference. Breast Cancer. 8: 298304.
Group E B C T C (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 365: 1687-1717.
Jones S E S, Michael A (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology. 24: 5381-5387.
Wong H L (2006) A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Journal of Pharmacology and Experimental Therapeutics. 317: 1372-1381.
Pluen A (2001) Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proceedings of the National Academy of Sciences. 98: 4628-4633.
Jain R K (2001) Delivery of molecular and cellular medicine to solid tumors1. Advanced drug delivery reviews. 46: 149168.
Hu Q and G H Baeg (2017) Role of epigenome in tumorigenesis and drug resistance. Food and Chemical Toxicology. 109: 663-668.
Kazanets, A (2016) Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 1865: 275-288.
Vijayaraghavalu S (2012) Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Molecular pharmaceutics. 10: 337-352.
Young C S (2017) Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget. 8: 51429.
Sun Y L (2012) Role of ABC transporters in cancer chemotherapy. Chinese journal of cancer, 31: 51.
Mukohara T (2011) Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer. Cancer Science, 102: 1-8.
Wong R.S (2011) Apoptosis in cancer: from pathogenesis to treatment. Journal of Experimental & Clinical Cancer Research. 30: 87.
Green S K, A Frankel and R S Kerbel (1999) Adhesiondependent multicellular drug resistance. Anti-cancer drug design. 14: 153-168.
Durand R E and P L Olive (2001) Resistance of tumor cells to chemo-and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods in cell biology, 64: 211-233.
Gottesman M M, T Fojo and S E Bates (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer. 2: 48.
Ambudkar S V (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual review of pharmacology and toxicology,. 39: 361-398.
Endicott J A and V Ling (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annual review of biochemistry. 58: 137-171.
Booser D J (2002) Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer chemotherapy and pharmacology. 50: 6-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Isaac Sokoato Momoh, Victor Duniya Sheneni, Isaac Eleojo Shaibu
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
